News | FFR Technologies | May 29, 2018

ORBITA: FFR and iFR as Predictors Placebo-controlled Response to PCI

Physiology-stratified analysis of ORBITA Trial for percutaneous coronary intervention in stable single vessel coronary artery disease

The ORBITA Trial showed FFR and iFR are good predictors of PCI outcomes. This was a 2018 PCR late-breaker.

May 29, 2018 — The first placebo-controlled trial that looked at how fractional flow reserve (FFR) and instantaneous wave-free ratio (iFR) predicts the efficacy of percutaneous coronary intervention (PCI) found angioplasty improved ischemia. The invasive physiology data from 196 patients from the Objective Randomized Blinded Investigation with optimal medical Therapy of Angioplasty in stable angina (ORBITA) Trial was presented as a late-breaking trial at the 2018 EuroPCR conference.

“In particular, from this study, we’ve seen that the degree of ischemia on iFR and FFR entirely predicts the degree of improvement in ischemia that’s seen on dobutamine stress echo," said Rasha Al-Lamee, interventional cardiology consultant at Imperial College London and principal investigator for ORBITA. "What this means for physicians is that we will be able to use the iFR and FFR data before an intervention to predict exactly how much improvement in ischemia we can expect for our patients following successful stenting. This is the first placebo-controlled evidence we have had of this kind.”

FFR and iFR were used as predictors of placebo-controlled efficacy of PCI in stable coronary artery disease. Patients enrolled had stable angina and single vessel coronary artery disease. At pre-randomization the majority had Canadian Cardiovascular Society class II or III symptoms (150/196, 76.5%). Mean FFR and iFR were 0.69±0.16 and 0.76±0.22, respectively. 97% of patients had one or more positive noninvasive or invasive tests for ischemia. 

FFR and iFR was performed solely for this research question, and so the interventionalist in the catheterization laboratory was blinded to the results. Assessment of response variables, treadmill exercise time, stress echo score, symptom frequency, and angina severity were performed at pre-randomization and blinded follow-up. Effects were calculated by analysis of covariance. The ability of FFR and iFR to predict placebo-controlled changes in response variables was tested using regression modeling.

The placebo-controlled effect of PCI was more clearly seen by stress echo score and freedom from angina than change in treadmill exercise time. The estimated effect of PCI on between-arm pre-randomization-adjusted total exercise time was 20.7s (95% CI: -4.0 to 45.5; p=0.100) with no dependence on FFR (pinteraction=0.318) and iFR (pinteraction=0.523). PCI improved stress echo score more than placebo (1.07 segment units, 95% CI: 0.70 to 1.44, p<0.00001). The placebo-controlled effect of PCI on stress echo score increased progressively with decreasing FFR (pinteraction<0.00001) and decreasing iFR (pinteraction<0.00001). PCI resulted in more patient-reported freedom from angina than placebo (49.5% versus 31.5%; OR 2.47, 95% CI: 1.30 to 4.72; p=0.006) but neither FFR (pinteraction=0.693) nor iFR (pinteraction=0.761) modified this effect.

This report of ORBITA stratified by invasive haemodynamic measures of stenosis severity provides the first placebo-controlled evidence of the association between FFR and iFR and the magnitude of benefit attributable to PCI.

"This is the first placebo-controlled trial looking at how invasive physiology predicts the efficacy of PCI," Said Al-Lamee. "In this publication and in the primary publication in The Lancet we saw that angioplasty improved ischemia as assessed by dobutamine stress echo. However, in this analysis we were also able to assess an additional secondary endpoint of freedom from angina.  What is most interesting is that we found that angioplasty increased the number of patients who were free of angina by 20 absolute percentage points. For physicians, this means that one in five patients that we treat with angioplasty vs. placebo will be more likely to be free from angina. For our patients, this is one of the most important things we can tell them, that they are more likely to become symptom free.”

He said the next step for ORBITA is to look at the degree to which stress echo itself predicts the placebo-controlled impact of PCI. “In order to build on some of the questions answered in ORBITA as well as being able to apply ORBITA to a wider patient base, we are also preparing for ORBITA 2 which will be a larger trial, with wider inclusion criteria for patients with stable angina,” Al-Lamee concluded.

Links to other 2018 EuroPCR late-breaking trials
 


Related Content

News | Cardiovascular Clinical Studies

September 19, 2023 — A mathematical and computational model of the human heart entirely developed at Politecnico di ...

Home September 19, 2023
Home
News | Cardiovascular Clinical Studies

September 18, 2023 — Pregnant women with a history of substance abuse face a dramatically increased risk of death from ...

Home September 18, 2023
Home
News | Cardiovascular Clinical Studies

September 18, 2023 — Biosense Webster, Inc., a global leader in cardiac arrhythmia treatment and part of Johnson & ...

Home September 18, 2023
Home
News | Cardiovascular Clinical Studies

September 18, 2023 — Anthos Therapeutics, Inc., a clinical stage company developing innovative therapies for ...

Home September 18, 2023
Home
News | Cardiovascular Clinical Studies

September 14, 2023 — Myocardial infarction, the number one cause of sudden death in adults and the number two cause of ...

Home September 14, 2023
Home
News | Cardiovascular Clinical Studies

September 12, 2023 — Mineralys Therapeutics, Inc. has presented final results from the Target-HTN Phase 2 trial of ...

Home September 12, 2023
Home
News | Cardiovascular Clinical Studies

September 12, 2023 — Merck announced new analyses from studies of sotatercept, Merck’s novel investigational activin ...

Home September 12, 2023
Home
News | Cardiovascular Clinical Studies

September 8, 2023 — Imbria Pharmaceuticals, Inc., a clinical stage, cardiometabolic company dedicated to developing ...

Home September 08, 2023
Home
News | Cardiovascular Clinical Studies

September 8, 2023 — Patients of African ancestry with dilated cardiomyopathy (DCM) are less likely to have clinically ...

Home September 08, 2023
Home
News | Cardiovascular Clinical Studies

September 6, 2023 — Magenta Medical, developer of the Elevate heart pump system, an FDA Designated Breakthrough Device ...

Home September 06, 2023
Home
Subscribe Now